A Phase 1 interventional study of Pharmacokinetic sampling and AZD9291 in Advanced Non Small Cell Lung Cancer and Advanced (Inoperable) Non Small Cell Lung Cancer, sponsored by AstraZeneca. Completed at 16 sites in 6 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-11-19.
Sponsored by AstraZeneca · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 43 under way, 8 of them phase 3. osimertinib · Carcinoma, Non-Small-Cell Lung.
Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, this one is the 59th largest by enrollment, is one of 10 that started in 2014, is one of 18 in phase 1, and was the 5th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →20 of the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung are open now, in 7 countries. Recruiting first, the newest first:
Maastricht University Medical Center · Sites in Netherlands
Ages 18+
AstraZeneca · Sites in China
Ages 18+
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–99
Shanghai Chest Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, osimertinib is the treatment under test here. Read study by study →
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 52 · Phase 3 12 · Phase 4 4
First in 2013; this study’s year is marked. 10 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is below the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 51 across the 90 interventional studies. Of the 32 that completed or were terminated, 21 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 90 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca: 25 open now, 78 under way, 28 of them phase 3. Of 123 finished, 45 (37%) have results posted.
Among the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 113th largest by enrollment of the 137 interventional ones that give a count, is one of 14 that started in 2014, is one of 36 in phase 1, and was the 61st registered.
AstraZeneca’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
10 of the studies testing osimertinib in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05120349Phase 3AstraZenecaA Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection | 2027-08-02 |
| NCT04285671Jonsson Comprehensive Cancer CenterNecitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer | 2026-12-02 |
| NCT04322890Hunan Province Tumor HospitalTreatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation | 2026-12-24 |
| NCT07323641Jonsson Comprehensive Cancer CenterTelisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer | 2027-02-01 |
| NCT07485452Maastricht University Medical CenterBoosting Osimertinib Blood Brain Barrier Penetration | 2027-06 |
Add all 10 to your calendar (.ics) → With an account.
Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among AstraZeneca’s 209 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This is a 2 part study in patients with EGFRm+ non small cell lung cancer (NSCLC), whose disease has progressed on an EGFRm TKI, who are refractory or resistant to standard therapy. Part A will assess the effect of multiple oral doses of itraconazole on the single dose pharmacokinetic (PK) parameters of AZD9291. On completion of Part A, patients may continue to take AZD9291 tablets (Part B) following the collection of the 216 hour sample on Day 19 if they and the Investigator deem it appropriate, until such time as their disease progresses, the Investigator believes they are no longer deriving clinical benefit, or they stop taking AZD9291 for any other reason
For inclusion in the study, patients should fulfil the following criteria:
Patients should not enter the study if any of the following exclusion criteria are fulfilled:
12. Concomitant medication for use with itraconazole (including, but not limited to): cisapride, oral midazolam, nisoldipine, pimozide, quinidine, dofetilide, triazolam, levacetylmethadol (levomethadyl), 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA)- reductase inhibitors metabolized by CYP3A4, such as lovastatin and simvastatin, ergot alkaloids metabolized by CYP3A4, such as dihydroergotamine, ergometrine (ergonovine), ergotamine and methylergometrine (methylergonovine).
13. For optional genetic research: Previous allogenic bone marrow transplant or non-leukocyte depleted whole blood transfusion within 120 days of sample collection.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sequential treatments of AZD9291 alone followed by AZD9291+itraconazole, with a washout period in between.
Procedure: Pharmacokinetic sampling · Drug: AZD9291 · Drug: Itraconazole
Blood samples taken pre and post dosing with AZD9291+/- itraconazole
AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.
Itraconazole tablets: 2x100mg bd, Part A days 6 to 19 only
Cmax of AZD9291
Pharmacokinetics of AZD9291 by assessment of maximum plasma AZD9291 concentration
Time frame: Blood samples collected on Day 1 and Day 10 at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 216 hours post AZD9291 dose in Part A.
AUC of AZD9291
Pharmacokinetics of AZD9291 by assessment of area under the plasma concentration time curve from zero to infinity
Time frame: Blood samples collected on Day 1 and Day 10 at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 216 hours post AZD9291 dose in Part A.
AUC(0-120) of AZD9291
Pharmacokinetics of AZD9291 by assessment of area under the plasma concentration time curve from zero to 120 hours
Time frame: Blood samples collected on Day 1 and Day 10 at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 216 hours post AZD9291 dose in Part A.
AUC(0-t) of AZD9291
Pharmacokinetics of AZD9291 by assessment of area under the plasma concentration curve from time zero to last quantifiable dose
Time frame: Blood samples collected on Day 1 and Day 10 at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 216 hours post AZD9291 dose in Part A.
Tmax of AZD9291
Pharmacokinetics of AZD9291 by assessment of time to Cmax
Time frame: Blood samples collected on Day 1 and Day 10 at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 216 hours post AZD9291 dose in Part A.
t1/2 of AZD9291
Pharmacokinetics of AZD9291 by assessment of the terminal half-life
Time frame: Blood samples collected on Day 1 and Day 10 at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 216 hours post AZD9291 dose in Part A.
CL/F of AZD9291
Rate and extent of absorption of AZD9291 by assessment of apparent clearance following oral administration
Time frame: Blood samples collected on Day 1 and Day 10 at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 216 hours post AZD9291 dose in Part A.
Vz/F of AZD9291
Rate and extent of absorption of AZD9291 by assessment of the apprarent volume of distribution
Time frame: Blood samples collected on Day 1 and Day 10 at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 216 hours post AZD9291 dose in Part A.
Cmax of AZ5104
Pharmacokinetics of AZ5104 (metabolite to AZD9291) by assessment of maximum plasma AZ5104 concentration
Time frame: Blood samples collected on Day 1 and Day 10 at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 216 hours post AZD9291 dose in Part A.
AUC of AZ5104
Pharmacokinetics of AZ5104 (metabolite to AZD9291) by assessment of area under the plasma concentration time curve from zero to infinity
Time frame: Blood samples collected on Day 1 and Day 10 at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 216 hours post AZD9291 dose in Part A.
Cmax of AZ7550
Pharmacokinetics of AZ7550 (metabolite to AZD9291) by assessment of maximum plasma AZ7550 concentration
Time frame: Blood samples collected on Day 1 and Day 10 at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 216 hours post AZD9291 dose in Part A.
AUC of AZ7550
Pharmacokinetics of AZ7550 (metabolite to AZD9291) by assessment of area under the plasma concentration time curve from zero to infinity
Time frame: Blood samples collected on Day 1 and Day 10 at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 216 hours post AZD9291 dose in Part A.
First subject enrolled: 6 November 2014; Last Subject Last Visit Part A: 3 April 2015 and Part B: 31 March 2016. Study performed at 15 sites across Asia, North America and Western Europe. Part A assessed effect of multiple doses of itraconazole on PK of AZD9291; Part B allowed subjects further access to AZD9291 and provided additional safety data.
| Milestone | AZD9291 and Itraconozole (Part A); AZD9291 Alone (Part B) |
|---|---|
| Started | 39 |
| Completed | 38 |
| Not completed | 1 |
| Milestone | AZD9291 and Itraconozole (Part A); AZD9291 Alone (Part B) |
|---|---|
| Started | 39 |
| Completed | 38 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
| Milestone | AZD9291 and Itraconozole (Part A); AZD9291 Alone (Part B) |
|---|---|
| Started | 38 |
| Completed | 16 |
| Not completed | 22 |
| Withdrew: Adverse event | 3 |
| Withdrew: Disease progression | 15 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Death | 3 |
Pharmacokinetics of AZD9291 by assessment of maximum plasma AZD9291 concentration
| nM | AZD9291 Alone | AZD9291+Itraconazole |
|---|---|---|
| Cmax of AZD9291 | 242.5 (88.8 to 704) | 201.7 (78.2 to 676) |
Pharmacokinetics of AZD9291 by assessment of area under the plasma concentration time curve from zero to infinity
| nM*h | AZD9291 Alone | AZD9291+Itraconazole |
|---|---|---|
| AUC of AZD9291 | 13520 (6510 to 40400) | 17090 (7130 to 59600) |
Pharmacokinetics of AZD9291 by assessment of area under the plasma concentration time curve from zero to 120 hours
| nM*h | AZD9291 Alone | AZD9291+Itraconazole |
|---|---|---|
| AUC(0-120) of AZD9291 | 10280 (4980 to 27500) | 11370 (5100 to 37500) |
Pharmacokinetics of AZD9291 by assessment of area under the plasma concentration curve from time zero to last quantifiable dose
| nM*h | AZD9291 Alone | AZD9291+Itraconazole |
|---|---|---|
| AUC(0-t) of AZD9291 | 12260 (6090 to 33600) | 14520 (6280 to 49600) |
Pharmacokinetics of AZD9291 by assessment of time to Cmax
| hours | AZD9291 Alone | AZD9291+Itraconazole |
|---|---|---|
| Tmax of AZD9291 | 4.00 (2.03 to 11.87) | 6.04 (3.00 to 72.00) |
Pharmacokinetics of AZD9291 by assessment of the terminal half-life
| hours | AZD9291 Alone | AZD9291+Itraconazole |
|---|---|---|
| t1/2 of AZD9291 | 61.05 (38.7 to 131) | 78.36 (56.3 to 150) |
Rate and extent of absorption of AZD9291 by assessment of apparent clearance following oral administration
| L/h | AZD9291 Alone | AZD9291+Itraconazole |
|---|---|---|
| CL/F of AZD9291 | 11.84 (3.96 to 24.6) | 9.368 (2.69 to 22.5) |
Rate and extent of absorption of AZD9291 by assessment of the apprarent volume of distribution
| L | AZD9291 Alone | AZD9291+Itraconazole |
|---|---|---|
| Vz/F of AZD9291 | 1019 (491 to 2310) | 1059 (344 to 2630) |
Pharmacokinetics of AZ5104 (metabolite to AZD9291) by assessment of maximum plasma AZ5104 concentration
| nM | AZD9291 Alone | AZD9291+Itraconazole |
|---|---|---|
| Cmax of AZ5104 | 8.568 (2.36 to 23.4) | 5.746 (2.15 to 15.8) |
Pharmacokinetics of AZ5104 (metabolite to AZD9291) by assessment of area under the plasma concentration time curve from zero to infinity
| nM*h | AZD9291 Alone | AZD9291+Itraconazole |
|---|---|---|
| AUC of AZ5104 | 1155 (367 to 4360) | 941.4 (337 to 2620) |
Pharmacokinetics of AZ7550 (metabolite to AZD9291) by assessment of maximum plasma AZ7550 concentration
| nM | AZD9291 Alone | AZD9291+Itraconazole |
|---|---|---|
| Cmax of AZ7550 | 4.321 (1.64 to 11.7) | 1.897 (0.659 to 5.42) |
Pharmacokinetics of AZ7550 (metabolite to AZD9291) by assessment of area under the plasma concentration time curve from zero to infinity
| nM*h | AZD9291 Alone | AZD9291+Itraconazole |
|---|---|---|
| AUC of AZ7550 | 624.1 (210 to 1700) | 292.1 (158 to 578) |
Collected over Approximately 3 weeks for Part A; up to approximately 15.5 months for Part B and approximately 16 months for Overall (Parts A and B combined).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Overall | — | 12/39 (30.8%) | 39/39 (100%) |
| Part A | — | 3/39 (7.7%) | 24/39 (61.5%) |
| Part B | — | 9/38 (23.7%) | 38/38 (100%) |
| Event | Overall | Part A | Part B |
|---|---|---|---|
| PneumoniaInfections and infestations | 3/39 | 1/39 | 2/38 |
| Urinary tract infectionInfections and infestations | 2/39 | 0/39 | 2/38 |
| Hepatic enzyme increasedInvestigations | 2/39 | 1/39 | 1/38 |
| Gastric ulcerGastrointestinal disorders | 1/39 | 0/39 | 1/38 |
| InfluenzaInfections and infestations | 1/39 | 0/39 | 1/38 |
| Metapneumovirus infectionInfections and infestations | 1/39 | 0/39 | 1/38 |
| Bronchopleural fistulaRespiratory, thoracic and mediastinal disorders | 1/39 | 0/39 | 1/38 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/39 | 0/39 | 1/38 |
| Respiratory syncytial virus infectionInfections and infestations | 1/39 | 1/39 | 0/38 |
| Event | Overall | Part A | Part B |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 15/39 | 2/39 | 13/38 |
| NauseaGastrointestinal disorders | 14/39 | 7/39 | 10/38 |
| FatigueGeneral disorders | 12/39 | 3/39 | 9/38 |
| Decreased appetiteMetabolism and nutrition disorders | 12/39 | 1/39 | 11/38 |
| VomitingGastrointestinal disorders | 10/39 | 6/39 | 6/38 |
| ParonychiaInfections and infestations | 8/39 | 0/39 | 8/38 |
| ConstipationGastrointestinal disorders | 8/39 | 2/39 | 6/38 |
| DizzinessNervous system disorders | 7/39 | 4/39 | 3/38 |
| HeadacheNervous system disorders | 7/39 | 1/39 | 6/38 |
| AnaemiaBlood and lymphatic system disorders | 6/39 | 1/39 | 5/38 |
| Age, Continuous(years) | AZD9291 and Itraconozole (Part A); AZD9291 Alone (Part B) |
|---|---|
| Mean | 58.8 ± 10.73 |
| Sex: Female, Male(Participants) | AZD9291 and Itraconozole (Part A); AZD9291 Alone (Part B) |
|---|---|
| Female | 27 |
| Male | 12 |
| Race (NIH/OMB)(Participants) | AZD9291 and Itraconozole (Part A); AZD9291 Alone (Part B) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 29 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 10 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Nov 2014 to primary completion in Apr 2015, 4 months.
Results were first posted in Apr 2016, 1 year after primary completion.
Of 473 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 4 months is below that.
Counting every sponsor, half of 699 studies reached it within 50 months; a quarter within 31 and three quarters within 70.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Osimertinib
Carcinoma, Non-Small-Cell Lung →